Hepatitis C virus (HCV) is a global health problem, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma, superoxide and peroxide that arise during viral infection and damage hepatocytes and surrounding cells. Hepatocytes normally up-regulate oxidative defense enzymes to maintain redox balance and prevent injury. An important antioxidative enzyme is heme oxygenase-1 (HO-1) that is induced in response to oxidative stress in humans and animal models. Although the role of HO-1 in human liver disease has not been well-studied, available evidence suggests that the enzyme is usually up-regulated in response to injury. In contrast, recent data by our group have shown that HO-1 expression is down-regulated in HCV infected liver samples and that the HCV core protein transcriptionally down-regulates the enzyme in vitro. Collectively, these data suggest that suppression of HO-1 expression by HCV may contribute to hepatic injury. Our overall objective is to determine the role and importance of HO-1 in HCV liver disease and the pathologic consequences that result when the enzyme is down regulated by HCV. Our central hypothesis is that HO-1 is an important hepatocellular defense enzyme that overall prevents hepatocyte injury. Hepatitis C virus transcriptionally down regulates expression of HO-1 during chronic infection, which alters the susceptibility and response of the hepatocyte to injury. Using a large human liver sample bank for the in vivo studies and a variety of HCV protein and full length viral constructs in vitro, we will test the central hypothesis and accomplish the major objective by undertaking experiments of three specific aims: 1) We will test the hypothesis that down regulation of HO-1 in HCV liver disease is significantly related to, and important for hepatocyte injury in vivo. 2) We will test the hypothesis that HO-1 is transcriptionally down-regulated in contrast to HO-2 in Huh-7.5 hepatocytes expressing FL HCV replicons. 3) We will test the hypothesis that hepatocytes expressing FL HCV replicons are more sensitive to cellular injury and oxidative stress. We also hypothesize that over-expression of HO-1 will at least partially reverse the untoward effects of FL HCV replication and expression on cellular oxidative redox balance. These experiments will increase our understanding of the importance of HO-1 in HCV and other liver diseases and the putative injurious consequences that result when the enzyme is down-regulated. Further study of the regulation of HO-1 expression by HCV will lay the foundation for-improved therapeutic options1 for patients with chronic HCV disease such as targeted antioxidant gene therapy and selective antioxidants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DK068453-01A1
Application #
6921206
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2005-05-01
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
1
Fiscal Year
2005
Total Cost
$188,220
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Schmidt, Warren N; Nelson, David R; Pawlotsky, Jean-Michel et al. (2014) Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 12:728-37
Zhu, Zhaowen; Mathahs, M Meleah; Schmidt, Warren N (2013) Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease. J Infect Dis 208:1653-63
Bandyopadhyay, Sarmistha; Friedman, Robin C; Marquez, Rebecca T et al. (2011) Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis 203:1753-62
Marquez, Rebecca T; Bandyopadhyay, Sarmistha; Wendlandt, Erik B et al. (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90:1727-36
Zhu, Zhaowen; Wilson, Anne T; Luxon, Bruce A et al. (2010) Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase? Hepatology 52:1897-905
Ali, Sobia; Stolpen, Alan H; Schmidt, Warren N (2010) Portosystemic encephalopathy due to mesoiliac shunt in a patient without cirrhosis. J Clin Gastroenterol 44:381-3
Zhu, Zhaowen; Wilson, Anne T; Gopalakrishna, Kota et al. (2010) Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells. J Med Virol 82:239-48
Kayali, Zeid; Herring, Jason; Baron, Pedro et al. (2009) Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 24:1030-7
Zhu, Zhaowen; Wilson, Anne T; Mathahs, M Meleah et al. (2008) Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 48:1430-9
Wen, Feng; Brown, Kyle E; Britigan, Bradley E et al. (2008) Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity. Cell Biol Toxicol 24:175-88

Showing the most recent 10 out of 11 publications